Edgewise Therapeutics, Inc.

EWTX • Biotechnology

$43.07

▲ +1.12 (+2.67%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$4.64B

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 19.85Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 7 ago 2026, 12:43 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$43.07

Change2.67%

Shares Out107.67M

Market Cap$4.64B

Enterprise Value$4.18B

52W Range12.30 - 48.40

Beta0.28

P/E-23.51

P/B10.35

P/FCF-29.05

EV/EBITDA-20.66

EV/FCF-26.19

Price$43.07

Change2.67%

Shares Out107.67M

Market Cap$4.64B

Enterprise Value$4.18B

52W Range12.30 - 48.40

Beta0.28

P/E-23.51

P/B10.35

P/FCF-29.05

EV/EBITDA-20.66

EV/FCF-26.19

Earnings Yield-4.25%

FCF Yield-3.44%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio19.85

Quick Ratio19.85

Target$51.90

Target Upside20.50%

Target Median$52.00

Target Range36.00 - 66.00

Volume1.19M

Avg Volume1.44M

EPS Surprise0.04

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

63/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 19.85Rentabilidad débil

Analyst view

Analyst sentiment and price target

EWTX

Analyst sentiment

Based on 11 analyst votes · 2026-09-05

91/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-07

Bajo

$25.00

Promedio

$49.09

Mediana

$52.00

Alto

$66.00

Resumen de la compañía

IPO: 3/26/2021

Industria: Biotechnology

P/B i: 10.35

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 19.85

Ratio rápido: 19.85

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 1 venta interna de alto volumen detectada

ROOT JONATHAN D

Transacción: 06/05/2026

COMPRA

Cambio

+16,377

Precio

$35.59

Presentación

07/17/2026

Tipo

COMPRA

Russell Alan J

Transacción: 07/01/2026

VENTA

Cambio

-69,648

Precio

$39.41

Presentación

07/02/2026

Tipo

VENTA

Russell Alan J

Transacción: 07/01/2026

VENTA

Cambio

-130,352

Precio

$0.45

Presentación

07/02/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
ROOT JONATHAN D	COMPRA	+16,377	$35.59	06/05/2026	07/17/2026
Russell Alan J	VENTA	-69,648	$39.41	07/01/2026	07/02/2026
Russell Alan J	VENTA	-130,352	$0.45	07/01/2026	07/02/2026
Fox Jonathan C	COMPRA	+319	Not reported	07/01/2026	07/01/2026
Morris Arlene	COMPRA	+16,377	$35.59	06/05/2026	06/17/2026
Thompson Peter A.	COMPRA	+16,377	$35.59	06/05/2026	06/17/2026
Brege Laura	COMPRA	+16,377	$35.59	06/05/2026	06/17/2026
Fox Jonathan C	COMPRA	+16,377	$35.59	06/05/2026	06/16/2026
Martin Christopher Nathan	COMPRA	+16,377	$35.59	06/05/2026	06/16/2026
Edris Badreddin	COMPRA	+5,619	Not reported	06/05/2026	06/16/2026
Edris Badreddin	COMPRA	+8,188	$35.59	06/05/2026	06/16/2026
Donovan Joanne M.	VENTA	-50,000	$38.57	05/05/2026	05/05/2026
Donovan Joanne M.	VENTA	-50,000	$7.08	05/05/2026	05/05/2026
Donovan Joanne M.	VENTA	-5,230	$31.29	05/04/2026	05/05/2026
Fox Jonathan C	COMPRA	+339	Not reported	04/01/2026	04/03/2026
Donovan Joanne M.	VENTA	-28,662	$32.31	04/01/2026	04/02/2026
Donovan Joanne M.	VENTA	-28,662	$7.08	04/01/2026	04/02/2026
Donovan Joanne M.	VENTA	-21,338	$32.12	03/31/2026	03/31/2026
Donovan Joanne M.	VENTA	-21,338	$7.08	03/31/2026	03/31/2026
Donovan Joanne M.	VENTA	-6,735	$30.98	03/27/2026	03/30/2026

Sobre la compañía

Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Fuente - Link

Competidores

CLDX GLPG GPCR JANX MESO NUVB OCUL QURE VERA VRDN

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

BOULDER, Colo., Sept. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that on August 31, 2026, Edgewise granted inducement stock options to purchase a total of 21,000 shares of Edgewise's common stock and awards of inducement restricted stock units (each, an "RSU award") covering a total of 10,501 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

PRNewsWire

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany.

PRNewsWire

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

Edgewise Therapeutics (EWTX) has transformed into a well-capitalized cardiovascular drug developer following the $1.55B sale of sevasemten to Servier. EDG-7500, EWTX's lead asset, demonstrated robust Phase 2 efficacy in both obstructive and nonobstructive HCM, with a differentiated safety and workflow profile. EWTX's cash runway now extends into the early 2030s, enabling late-stage pipeline advancement without shareholder dilution and retaining up to $1.1B in milestone upside.

Seeking Alpha

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) – – Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline – BOULDER, Colo., Aug. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights.

PRNewsWire

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential approval — BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion.

PRNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-07	-0.5	-0.46	0.04
2026-02-26	-0.43	-0.47	-0.04
2025-11-06	-0.4	-0.39	0.01
2025-08-07	-0.42	-0.34	0.08
2025-05-08	-0.45	-0.43	0.02
2025-03-03	-0.39	-0.42	-0.03
2024-11-07	-0.37	-0.36	0.01
2024-08-08	-0.36	-0.34	0.02
2024-05-09	-0.39	-0.33	0.06
2024-02-22	-0.44	-0.47	-0.03
2023-11-09	-0.4	-0.41	-0.01
2023-08-10	-0.41	-0.34	0.07